TY - JOUR T1 - Emergence of <em>mcr-9.1</em> in ESBL-producing Clinical Enterobacteriaceae in Pretoria, South Africa: Global Evolutionary Phylogenomics, Resistome and Mobilome JF - medRxiv DO - 10.1101/2019.12.24.19015784 SP - 2019.12.24.19015784 AU - John Osei Sekyere AU - Nontuthuko E. Maningi AU - Lesedi Modipane AU - Nontombi Marylucy Mbelle Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/30/2019.12.24.19015784.abstract N2 - Background Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are critical-priority pathogens that cause substantial fatalities. With the emergence of mobile mcr genes mediating resistance to colistin in Enterobacteriaceae, clinicians are now left with little therapeutic options.Methods Eleven clinical Enterobacteriaceae strains with resistance to cephems and/or colistin were genomically analysed to determine their resistome, mobilome, and evolutionary relationship to global strains. The global phylogenomics of mcr-9.1-bearing genomes were further analysed.Results &amp; conclusion Ten isolates were ESBL positive. The isolates were multidrug-resistant and phylogenetically related to global clones, but distant from local strains. Multiple resistance genes, including blaCTX-M-15 blaTEM-1 and mcr-9.1 were found in single isolates; ISEc9, IS19, and Tn3 transposons bracketed blaCTX-M-15 and blaTEM-1. Common plasmid types included IncF, IncH and ColRNAI. Genomes bearing mcr-9.1 clustered into six main phyletic groups (A-F), with those of this study belonging to clade B. Enterobacter sp. and Salmonella sp. are the main hosts of mcr-9.1 globally, albeit diverse promiscuous plasmids disseminate mcr-9.1 across different bacterial species. Emergence of mcr-9.1 in ESBL-producing Enterobacteriaceae in South Africa is worrying due to the restricted therapeutic options. Intensive One Health molecular surveillance might discover other mcr alleles and inform infection management and antibiotic choices.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was secured for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data on this manuscript are available as supplemental information attached to this article. ER -